证券代码：688273 证券简称：麦澜德 公告编号：2025-047 南京麦澜德医疗科技股份有限公司 关于召开 2025 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 会议召开时间：2025 年 11 月 18 日 （星期二） 9:00-10:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2025 年 11 月 11 日 （星期二） 至 11 月 17 日 （星期一）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 （mld@medlander.com）进行提问。公司将在说明会上对投资者普遍关注的问题 进行回答。 南京麦澜德医疗科技股份有限公司（以下简称"公司"）已于 2025 年 10 月 23 日发布公司 2025 年第三季度报告，为便于广大投资者更全面深入地了解公 司 2025 年第 ...

证券代码：688273 证券简称：麦澜德 公告编号：2025-046 南京麦澜德医疗科技股份有限公司 2025年第三次临时股东会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东会召开的时间：2025 年 11 月 7 日 （二） 股东会召开的地点：南京市雨花台区凤展路 32 号 A2 栋北公司会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 46 | | --- | --- | | 普通股股东人数 | 46 | | 2、出席会议的股东所持有的表决权数量 | 60,493,804 | | 普通股股东所持有表决权数量 | 60,493,804 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 61.85 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 61.85 | （四） 表决方式 ...

致：南京麦澜德医疗科技股份有限公司 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民 共和国证券法》及中国证券监督管理委员会发布的《上市公司股东会规则》等规 定，北京市中伦律师事务所（以下简称"本所"）接受南京麦澜德医疗科技股份 有限公司（以下简称"公司"）的委托，指派本所律师对公司 2025 年第三次临 时股东会（以下简称"本次股东会"）进行见证并就相关事项出具本法律意见书。 北京市中伦律师事务所 关于南京麦澜德医疗科技股份有限公司 本法律意见书仅就本次股东会的召集人资格、召集和召开程序、出席本次股 东会人员的资格、会议表决程序是否符合法律、法规、规范性文件及《公司章程》 的规定以及表决结果是否合法有效发表意见，而不对本次股东会所审议的议案内 容以及该等议案所表述的相关事实或数据的真实性、准确性或合法性发表意见。 2025 年第三次临时股东会的 法律意见书 本法律意见书仅供公司本次股东会之目的使用，未经本所书面同意，不得用 作其他任何目的。 为出具本法律意见书，本所律师列席了本次股东会，并根据有关法律、法规、 规范性文件的规定和要求，按照律师行业公认的业务标准、道德规范和勤勉尽责 1 法律 ...

Core Viewpoint - 麦澜德's stock price has shown significant volatility, with a year-to-date increase of 73.20%, but a recent decline of 4.53% over the past five trading days, indicating potential market fluctuations and investor sentiment changes [1][2]. Company Overview - 南京麦澜德医疗科技股份有限公司, established on January 16, 2013, and listed on August 11, 2022, specializes in the research, production, sales, and services related to pelvic and postpartum rehabilitation products [1]. - The company's revenue composition includes: pelvic rehabilitation products (36.98%), reproductive rehabilitation products (33.10%), consumables and accessories (24.32%), sports rehabilitation products (2.77%), and other products (2.84%) [1]. Financial Performance - For the period from January to September 2025, 麦澜德 reported a revenue of 344 million yuan, reflecting a year-on-year growth of 4.01%, while the net profit attributable to shareholders was approximately 95.6 million yuan, showing a slight decrease of 0.07% [2]. - Since its A-share listing, 麦澜德 has distributed a total of 268 million yuan in dividends [3]. Shareholder and Market Activity - As of September 30, 2025, 麦澜德 had 6,402 shareholders, an increase of 17.23% from the previous period, with an average of 5,752 circulating shares per shareholder, down by 14.70% [2]. - The stock has seen significant trading activity, with a recent net inflow of 686,900 yuan from major funds, indicating ongoing interest from institutional investors [1].

南京麦澜德医疗科技股份有限公司 2025 年第三次临时股东会会议资料 南京麦澜德医疗科技股份有限公司 2025 年第三次临时股东会会议资料 目 录 | 2025 年第三次临时股东会会议须知 | 3 | | --- | --- | | 2025 年第三次临时股东会会议议程 | 5 | | 议案一：关于 2025 年前三季度利润分配方案的议案 | 7 | | 议案二：关于变更公司注册地址、修订《公司章程》并办理工商变更登记的议案8 | | 南京麦澜德医疗科技股份有限公司 2025 年第三次临时股东会会议资料 证券代码：688273 证券简称：麦澜德 南京麦澜德医疗科技股份有限公司 2025 年第三次临时股东会会议资料 2025 年 11 月 南京麦澜德医疗科技股份有限公司 2025 年第三次临时股东会会议须知 为维护全体股东的合法权益，确保南京麦澜德医疗科技股份有限公司（以下 简称"公司"）股东会顺利进行，根据《中华人民共和国证券法》《中华人民共和国 公司法》等法律法规及《南京麦澜德医疗科技股份有限公司章程》和公司《股东 会议事规则》的相关规定，制定以下会议须知，请出席股东会的全体人员严格遵 守。 一、全体参会人 ...

Core Points - The company announced that its third extraordinary general meeting of shareholders in 2025 will review two proposals [1] Group 1: Profit Distribution Plan - For the first three quarters of 2025, the company reported a net profit of 95.9987 million yuan and plans to distribute a cash dividend of 3 yuan (including tax) for every 10 shares to all shareholders [1] - After deducting shares in the repurchase special account, the participating shares for the dividend distribution amount to 97.8079 million shares, with a total cash dividend of 29.3424 million yuan (including tax) proposed [1] - The company will not increase capital through reserve funds or issue bonus shares [1] Group 2: Company Registration Change - The second proposal involves changing the company's registered address and amending the Articles of Association, with the new registered address proposed to be No. 1 Hualin Road, Jiangning District, Nanjing City [1]

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected investment return that will outperform the market benchmark by more than 15% over the next 6-12 months [7]. Core Insights - The company reported a stable revenue growth of 4.01% year-on-year for the first three quarters of 2025, achieving a total revenue of 344 million yuan. The net profit attributable to the parent company was approximately 96 million yuan, showing a slight decrease of 0.07% year-on-year. In Q3 2025, the company generated a revenue of 103 million yuan, a year-on-year increase of 0.42%, while the net profit attributable to the parent company rose by 36.71% to 32 million yuan, primarily due to increased financial subsidies [5][6]. - The company is focusing on high-potential business areas such as brain-computer interfaces, with several key projects underway, including a national key research plan and various provincial initiatives aimed at developing advanced rehabilitation technologies [6]. Financial Performance Summary - For the fiscal year 2025, the company is projected to achieve revenues of 500 million yuan, with a year-on-year growth rate of 17.8%. The net profit attributable to the parent company is expected to be 117 million yuan, reflecting a growth of 15.0%. The earnings per share (EPS) for 2025 is estimated at 1.17 yuan, with a price-to-earnings (P/E) ratio of 34x [11][7]. - The financial forecasts for 2026 and 2027 indicate continued growth, with revenues expected to reach 613 million yuan and 748 million yuan, respectively, and net profits of 164 million yuan and 203 million yuan, with corresponding growth rates of 40.7% and 23.7% [11][7].

Core Insights - The medical device sector experienced a slight increase of 0.37% on October 24, with Mai Lande leading the gains [1] - The Shanghai Composite Index closed at 3950.31, up 0.71%, while the Shenzhen Component Index closed at 13289.18, up 2.02% [1] Medical Device Sector Performance - Top gainers included: - Mai Lande (688273) with a closing price of 41.92, up 6.31%, trading volume of 29,300 hands, and a transaction value of 121 million yuan [1] - Xiangyu Medical (688626) at 53.21, up 6.10%, with a trading volume of 41,100 hands and a transaction value of 216 million yuan [1] - Xiangsheng Medical (688358) at 35.27, up 4.75%, with a trading volume of 38,400 hands and a transaction value of 136 million yuan [1] - Other notable gainers included: - Aohua Endoscopy (688212) at 50.59, up 4.74%, with a transaction value of 225 million yuan [1] - Weisi Medical (688580) at 49.10, up 4.71%, with a transaction value of approximately 99.8 million yuan [1] Decliners in Medical Device Sector - Notable decliners included: - Chenguang Medical (920300) at 17.51, down 8.80%, with a trading volume of 124,000 hands [2] - Toukeng Life (300642) at 22.95, down 5.40%, with a trading volume of 175,700 hands [2] - Haitai New Light (688677) at 48.50, down 5.05%, with a trading volume of 38,800 hands [2] - Other significant decliners included: - Sino Medical (688108) at 28.00, down 4.73%, with a trading volume of 263,700 hands [2] - Tianchen Medical (688013) at 55.66, down 3.98%, with a trading volume of 19,200 hands [2] Capital Flow in Medical Device Sector - The medical device sector saw a net outflow of 654 million yuan from major funds, while retail investors contributed a net inflow of 455 million yuan [2]

Group 1 - The company announced a delay in its fundraising projects, extending the completion date to December 31, 2026, for the headquarters production base, R&D center, and marketing service projects [11][21][22] - The delay is attributed to external factors such as environmental controls, weather conditions, and resource limitations, which have hindered construction progress [11][12] - The company emphasizes that the delay does not change the project content, implementation subjects, or investment scale, ensuring no harm to shareholder interests [21][22] Group 2 - The company reported a net profit of approximately 95.99 million yuan for the first three quarters of 2025, with a proposed cash dividend of 0.30 yuan per share [27][26] - The profit distribution plan is subject to approval at the upcoming shareholder meeting [28][29] - The total number of shares eligible for the dividend is 97,807,857 after excluding shares held in the repurchase account [27][26] Group 3 - The company appointed a new securities affairs representative, Mr. Shen Jiazhen, to assist the board secretary [32][33] - Mr. Shen has the necessary qualifications and experience to fulfill his duties [35] - The company will continue to ensure compliance with relevant regulations in its operations [33][35] Group 4 - The company is undergoing a change of registered address, moving from Jiangning District to a new location in the same district [36][37] - The change is part of the company's operational adjustments and requires shareholder approval [36][37] - The company will also revise its articles of association accordingly [36][37] Group 5 - The company has scheduled its third extraordinary general meeting for November 7, 2025, to discuss various proposals, including the profit distribution plan [39][40] - The meeting will utilize both on-site and online voting systems to facilitate shareholder participation [40][41] - Shareholders must register in advance to attend the meeting and participate in voting [49][50]

Group 1 - The company announced the postponement of several key projects to December 31, 2026 [1] - The projects affected include the "Headquarters Production Base Construction Project," "Research and Development Center Construction Project," and "Marketing Services and Information Technology Construction Project" [1]